<DOC>
	<DOCNO>NCT00408798</DOCNO>
	<brief_summary>The purpose study examine prospectively safety efficacy Botulinum Toxin A ( Botox ) injection treatment patient alopecia areata scalp .</brief_summary>
	<brief_title>Treatment Alopecia Areata Scalp With Intradermal Injections Botulinum Toxin</brief_title>
	<detailed_description>Hypothesis Intralesional injection Botulinum Toxin A use treatment AA . Potential point action treatment include change neurotransmitter , either directly via neuroimmunologic mechanism influence cytocines responsible hair growth arrest alopecia areata . Justification Botulinum Toxin A antagonist Acetylcholine esterase use treat facial wrinkle hyperhidrosis . One ampoule contain Clostridium Botulinum Toxin Typ A ( 900kD ) 100 E , component human albumin sodium choride . The investigator learnt potential effect treatment AA personal communication . Objectives Over period 6 month , assess therapeutic efficacy safety regimen two interlesional injection Botulinum Toxin A 0 3 month , patient alopecia areata scalp , compare placebo . Research Method A total 20 eligible patient enrol study . All patient receive treatment one half target area placebo treatment half target area . Measurement severity scalp alopecia areata base extent terminal scalp hair loss . The Severity Alopecia Tool ( SALT ) use , determines percent scalp involvement disease calculate accord specification detailed Alopecia Areata Investigational Guidelines Olsen et al.. A circular target area least 4 cm diameter choose scalp . At visit 0 3 month visit 1 , two right quandrants target area inject either Botulinum Toxin A ( Botox ) dose 10 Units ( 0.1 cc ) saline 0.9 % total 0.1 cc . The left two quadrant injected medication . The patient know half target area inject drug placebo . The chosen side note patient documentation one investigator . The second investigator efficacy assessment qualitative scale know side treat Botulinum Toxin A placebo . At every visit , extent hair loss test area examine , base semi quantitative assessment scale range 0 100 . The investigator know side treat . There unpublished anecdotal report use efficacy Botulinumtoxin A patient alopecia areata . No evidence available fare .</detailed_description>
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Patients long stand alopecia areata , patch must least 4 cm diameter Intake drug interfere Botulinum toxin A gentamicin , tobramycin , clindamycin lincomycin ; medication use treat heart rhythm problem , quinidine ; medication use treat condition , myasthenia gravis , ALS Alzheimer 's disease . Neuromuscular disorder Myasthenia gravis LambertEatonSyndrome . Treatment another investigational drug within 4 week prior anticipate first treatment . Females pregnant , plan become pregnant study period , breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Treatment Alopecia areata intracutaneous injection Botulinum Toxin A</keyword>
</DOC>